ATE183922T1 - Verfahren zur hemmung der leaderless- proteinausscheidung mittels herzglykosiden, deren aglykone, oder derivate - Google Patents

Verfahren zur hemmung der leaderless- proteinausscheidung mittels herzglykosiden, deren aglykone, oder derivate

Info

Publication number
ATE183922T1
ATE183922T1 AT97906577T AT97906577T ATE183922T1 AT E183922 T1 ATE183922 T1 AT E183922T1 AT 97906577 T AT97906577 T AT 97906577T AT 97906577 T AT97906577 T AT 97906577T AT E183922 T1 ATE183922 T1 AT E183922T1
Authority
AT
Austria
Prior art keywords
inhibiting
aglycons
derivatives
cardiac glycosides
protein excretion
Prior art date
Application number
AT97906577T
Other languages
English (en)
Inventor
Robert Z Florkiewicz
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE183922T1 publication Critical patent/ATE183922T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97906577T 1996-02-12 1997-02-12 Verfahren zur hemmung der leaderless- proteinausscheidung mittels herzglykosiden, deren aglykone, oder derivate ATE183922T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/599,895 US5891855A (en) 1996-02-12 1996-02-12 Inhibitors of leaderless protein export

Publications (1)

Publication Number Publication Date
ATE183922T1 true ATE183922T1 (de) 1999-09-15

Family

ID=24401543

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97906577T ATE183922T1 (de) 1996-02-12 1997-02-12 Verfahren zur hemmung der leaderless- proteinausscheidung mittels herzglykosiden, deren aglykone, oder derivate

Country Status (9)

Country Link
US (4) US5891855A (de)
EP (2) EP0941733A3 (de)
JP (1) JPH11500454A (de)
AT (1) ATE183922T1 (de)
AU (1) AU706644B2 (de)
CA (1) CA2242245A1 (de)
DE (1) DE69700464T2 (de)
ES (1) ES2140215T3 (de)
WO (1) WO1997028808A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000075739A (ko) * 1997-02-26 2000-12-26 시블렉스 코포레이션 리더 서열이 없는 단백질 수송의 억제제
US6306613B1 (en) 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
US5910484A (en) * 1997-05-30 1999-06-08 The General Hospital Corporation Treatment of ischemic cardiac malfunction
GB9716273D0 (en) 1997-07-31 1997-10-08 Kimberly Clark Ltd Hand cleanser
GB9725480D0 (en) * 1997-12-01 1998-01-28 Univ London Cytokines and their use in the treatment of established chronic infections and cancers
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
KR20010042069A (ko) * 1998-03-20 2001-05-25 베니텍 오스트레일리아 리미티드 유전자 발현 조절방법
WO2000047215A2 (en) * 1999-02-12 2000-08-17 Cellpath, Inc. Methods for anti-tumor therapy
KR20010112944A (ko) * 1999-04-21 2001-12-22 이곤 이 버그 폴리뉴클레오티드 서열의 기능을 억제하기 위한 방법 및조성물
US6423885B1 (en) * 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
IL138529A0 (en) * 2000-09-18 2003-09-17 Yeda Res & Dev High level expression of heterologous proteins
CA2445889A1 (en) * 2001-05-02 2002-11-07 University Of South Florida Vector system for selection of genes encoding secreted proteins and membrane-bound proteins
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060234955A1 (en) * 2002-05-28 2006-10-19 Bette Pollard Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2529246A1 (en) * 2003-06-20 2004-12-29 Serum Biomedical Institute Method of producing recombinant dna molecules
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods
DE102004036047A1 (de) * 2004-07-24 2006-02-23 Bioghurt Biogarde Gmbh & Co. Kg Physiologisch aktive Zusammensetzung
EP1789090A2 (de) * 2004-09-02 2007-05-30 Bionaut Pharmaceuticals, Inc. Kombinatorische chemotherapiebehandlung mit na+/k+-atpase-hemmern
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
US20060135468A1 (en) 2004-09-02 2006-06-22 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using NA+/K+ ATPase inhibitors
US20080027010A1 (en) * 2004-09-02 2008-01-31 Bionaut Pharmaceuticals, Inc. Treatment of refractory cancers using Na+/K+-ATPase inhibitors
ATE509630T1 (de) * 2004-09-02 2011-06-15 Bionaut Pharmaceuticals Inc Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern
WO2006044916A2 (en) * 2004-10-18 2006-04-27 Bionaut Pharmaceuticals, Inc. Use of na+/ k+-atpase inhibitors and antagonists thereof
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
EP1993672B1 (de) * 2006-01-31 2012-01-25 The University of Toledo Verwendung kardiotonischer Steroiden als Na/K-ATPase liganden zur Hautbehandlung
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
EP2086528B1 (de) 2006-10-31 2016-10-26 University Of Toledo Na+/k+-atpase-spezifische peptidhemmer von src und kinasen der src-familie
EP2231165B1 (de) * 2007-11-13 2013-05-15 Phoenix Biotechnology Inc. Verfahren zur bestimmung der wahrscheinlichkeit einer therapeutischen antwort bei der krebs-chemotherapie mit herzglykosid
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
AU2009303460B9 (en) * 2008-10-14 2014-12-18 Nerium Biotechnology, Inc. Process for extracting cardiac glycodides and compositions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
ES2555252T3 (es) 2009-09-16 2015-12-30 The University Of Toledo Ligandos de Na/K-ATPasa, antagonistas de ouabaína, ensayos y uso de los mismos
WO2011088210A1 (en) 2010-01-13 2011-07-21 The University Of Toledo Materials and methods related to sodium/potassium adenosine triphosphatase and src
CN103980338B (zh) 2010-01-15 2017-04-26 苏州润新生物科技有限公司 蟾蜍灵衍生物、其药物组合物及用途
US8435525B1 (en) 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2670763B1 (de) 2011-02-02 2018-08-01 Suzhou Neupharma Co., Ltd Bestimmte chemische stoffe, zusammensetzungen und verfahren
CN102219821A (zh) * 2011-05-05 2011-10-19 沈阳药科大学 一类强心苷类化合物及其抗肿瘤用途
WO2013165924A1 (en) 2012-04-29 2013-11-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013169793A2 (en) * 2012-05-09 2013-11-14 Ipierian, Inc. Methods and compositions for tdp-43 proteinopathies
EP3685839A1 (de) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
US9561245B2 (en) 2012-09-06 2017-02-07 The Board Of Regents Of The University Of Texas System Combination treatments for melanoma
US9572828B2 (en) 2013-07-18 2017-02-21 The Board Of Regents Of The University Of Texas System Treatment for melanoma
MX2018015089A (es) 2016-06-10 2019-05-13 Boehringer Ingelheim Int Combinacion de linagliptina y metformina.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872103A (en) * 1986-11-26 1999-02-16 Belletti; Dino A. Prevention of mammary tumors by treatment with cardiac glycosides
US5545623A (en) * 1994-06-10 1996-08-13 Akira Matsumori Method of inhibiting secretion of inflammatory cytokines
US5556963A (en) 1994-08-05 1996-09-17 Oklahoma Medical Research Foundation Synthesis of 4-alkoxy-N-acetylneuraminic acid
WO1996004921A1 (en) * 1994-08-13 1996-02-22 Hong Keun Chung TNFα-SECRETION INHIBITOR CONTAINING SYRINGIN OR ITS AGLYCONE
US5627195A (en) * 1995-04-11 1997-05-06 Massachusetts Eye And Ear Infirmary Treatment for ocular inflammation

Also Published As

Publication number Publication date
DE69700464T2 (de) 2000-04-06
ES2140215T3 (es) 2000-02-16
EP0828497B1 (de) 1999-09-01
AU706644B2 (en) 1999-06-17
EP0941733A2 (de) 1999-09-15
EP0828497A1 (de) 1998-03-18
DE69700464D1 (de) 1999-10-07
US5891855A (en) 1999-04-06
WO1997028808A1 (en) 1997-08-14
JPH11500454A (ja) 1999-01-12
AU2123197A (en) 1997-08-28
US6071885A (en) 2000-06-06
EP0941733A3 (de) 1999-12-01
CA2242245A1 (en) 1997-08-14
US6281197B1 (en) 2001-08-28
US6107283A (en) 2000-08-22

Similar Documents

Publication Publication Date Title
ATE183922T1 (de) Verfahren zur hemmung der leaderless- proteinausscheidung mittels herzglykosiden, deren aglykone, oder derivate
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
DE3580599D1 (de) Verfahren und apparat zur roentgenstrahlenuntersuchung.
WO1998035985B1 (en) Protein markers for lung cancer and use thereof
DE69933504D1 (de) Apparat zur Gewebebestrahlung
DE68918943D1 (de) Gewebeentzusammensetzung und verfahren.
NO873753L (no) Periodisk biologisk luftbehandlingsprosess og system for denne.
DE3852378D1 (de) Mechanismus und Verfahren zur entgegengesetzten Flussteuerung.
DE68918103D1 (de) Verfahren zur überwachung des kollagenabbaus.
DE69712937D1 (de) Verfahren zur Bestimmung einer Kalibrierungskurve und Analyseverfahren und diesen Verfahren verwendendes Gerät.
FI943028A (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
DE3772423D1 (de) Verfahren zur herstellung von makrolidderivaten.
IT7925568A0 (it) Composizione adatta al controllo di tessuti e/o liquidi biologici emetodo impiegante la stessa.
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
ATA294087A (de) Verfahren zur herstellung von 5,6-dihydroxyindol und dessen 3-alkylderivat, zwischenverbindungen und verwendung
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
DE3766213D1 (de) Glycosidationskatalysator und verfahren zur herstellung von glycosid-derivaten.
ATE7230T1 (de) Neues protein pp11, ein verfahren zu seiner gewinnung und seine verwendung.
DE3861936D1 (de) Verfahren zur hochauszehrenden chromgerbung.
DE3577865D1 (de) Verfahren zur stabilisierung hydroxylgruppenhaltiger polymere des butadiens oder seiner substituierten derivate.
ATE323103T1 (de) Proteinmarker für ösophaguskrebs
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
DE69007143D1 (de) Apparat zur Kompensation der Belichtung für eine Röntgenanlage.
DE69521281T2 (de) Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
DE69822222D1 (de) Verfahren zur herstellung von beta-hydroxy-gamma-butyrolacton-derivaten und beta-(meth)acryloxy-gamma-butyrolacton-derivaten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties